BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 6476838)

  • 1. [Phase II study of mitoxantrone].
    Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase II study of mitoxantrone in advanced breast cancer].
    Ogawa M; Kubo K; Tominaga T; Nomura Y; Ota K; Yoshida M; Taguchi T; Hoshino A
    Gan To Kagaku Ryoho; 1986 May; 13(5):1980-4. PubMed ID: 3707156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase II study of 4'-O-tetrahydropyranyladriamycin(THP-ADM)].
    Nakada H; Ogawa M; Miyamoto H; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Usui N; Adachi K; Okada Y
    Gan To Kagaku Ryoho; 1984 Jan; 11(1):138-42. PubMed ID: 6696455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A phase II study of mitoxantrone in malignant lymphoma].
    Ibuka T; Sasaki T; Imai K; Sakai Y
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2612-7. PubMed ID: 3740861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A phase I trial of 4'-epiadriamycin].
    Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
    Kimura I; Ohnoshi T; Hiraki S; Ueoka H; Toyata K; Miyamoto H; Yamane T; Ueno K; Murashima M
    Gan No Rinsho; 1985 May; 31(6 Suppl):767-73. PubMed ID: 4040985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of mitoxantrone in advanced breast cancer.
    Pronzato P; Ardizzoni A; Conte PF; Gulisano M; Lionetto R; Repetto L; Scornavacche V; Sertoli MR; Rosso R
    Chemioterapia; 1986 Jun; 5(3):150-3. PubMed ID: 3719852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase II study of mitoxantrone in patients with acute leukemia].
    Kimura K; Yoshikawa S; Yoshikawa H; Yamada K; Hirano M; Ikeda Y; Ohta K; Ohara K; Kobayashi M; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2573-80. PubMed ID: 3740858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
    De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
    Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Jun; 10(6):1538-9. PubMed ID: 6347083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and clinical pharmacologic studies of mitoxantrone.
    Stewart JA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.
    Ehninger G; Weible KH; Heidemann EG; Waller HD
    Cancer Treat Rep; 1984 Oct; 68(10):1283-4. PubMed ID: 6525600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I trial of 4'-O-tetrahydropyranyl-doxorubicin (THP)--a multi-institutional cooperative study].
    Wakui A; Yokoyama M; Konno K; Nakai Y; Sakano T; Koyama Y; Imamura Y; Nakajima O; Niijima T; Akaza H
    Gan To Kagaku Ryoho; 1985 Jan; 12(1):118-24. PubMed ID: 3966806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
    Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
    Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study.
    Smyth JF; Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):15-8. PubMed ID: 6484578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.